Which company does Adagrasib come from?

Adagrasib (Adagrasib), developed by Mirati Therapeutics, is an orally effective, irreversible small molecule inhibitor of KRAS G12C mutant subtype. In December 2022, adagrasiib was first approved in the United States for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (as determined by U.S. Food and Drug Administration[FDA]-approved trials) who have received ≥ 1 prior systemic therapy.

Adagrasib is an irreversible inhibitor of KRAS G12C. It covalently binds to the mutated cysteine in KRAS G12C and locks the mutated KRAS protein in its inactive state, thereby preventing downstream signaling without affecting the wild-type KRAS protein. Adagarasib inhibits tumor cell growth and viability in cells harboring the KRAS G12C mutation and results in tumor regression with minimal off-target activity in a KRAS G12C-mutated tumor xenograft model. The drug is being developed in the United States for colorectal cancer (CRC) and clinical studies in solid tumors, including CRC, are ongoing in multiple countries.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.